A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

NewsGuard 100/100 Score
Jan 11 2010

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).

Pursuant to Nasdaq's rules, the Company was required to achieve a closing bid price of at least $1.00 per share for 10 consecutive trading days which was completed on January 4, 2010.

Source:

A.P. Pharma, Inc.

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

New urine-based test improves identification of high-grade prostate cancer
Study highlights growing burden of neurological disorders worldwide
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
SickKids study offers new path for pediatric rare disease clinical trials
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Georgetown study raises concerns over aspirin's role in breast cancer treatment
LabVantage celebrates customer success with record number of software deployments in FY 2024
Lancet Commission predicts sharp increase in global prostate cancer cases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study highlights global fertility decline and its implications for the future